Cevec and InVivo sign licence agreement

Cevec Pharmaceuticals, a German developer of a human expression system derived from amniocytes and InVivo BioTech Services, a contract manufacturer based in Hennigsdorf, Germany, have signed a licence agreement regarding the use of CAP-T technology for the production of recombinant proteins.

Under the licence, InVivo will offer fast and high quality production of diagnostic and preclinical grade material, including authentic human glycosylation patterns, using the CAP-T transient expression system.

CAP-T technology is based on CAP cells, the stable cell line from Cevec. The non-tumour origin cells have high expression rates of human proteins and grow in serum-free suspension culture and post-translational modifications are human-like. Process times are reduced by means of large-scale transient transfection.

"After launching our new transient cell in the US market we are delighted to have our first customers in Europe, not only using our stable expression system but also working with our new transiently expressing human cell line. With expression rates outperforming any other human system on the market, we offer our customers a unique state-of-the-art cell line," said Wolfgang Kintzel, cco of Cevec Pharmaceuticals.

Rainer Lichtenberger, ceo, added: "With our proprietary human cell lines, CAP for permanent producer cells for proteins and the novel CAP-T system, only Cevec is able to offer a unique range of versatile human cell expression systems to our customers, from early discovery to protein manufacture. This licence agreement contributes significantly to Cevec's goal of becoming the leading cell line supplier for protein production with human cell expression systems."